NCT02308332View on ClinicalTrials.gov

Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning

PHASE4CompletedINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions

Neurocognitive DeclineHIV Associated Neurocognitive Disorder

Interventions

DRUG

Eviplera

switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)

Trial Locations (1)

Unknown

UMC Utrecht, Utrecht

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

UMC Utrecht

OTHER